Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2342074rdf:typepubmed:Citationlld:pubmed
pubmed-article:2342074lifeskim:mentionsumls-concept:C0006684lld:lifeskim
pubmed-article:2342074lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:2342074lifeskim:mentionsumls-concept:C0038477lld:lifeskim
pubmed-article:2342074lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:2342074lifeskim:mentionsumls-concept:C0205549lld:lifeskim
pubmed-article:2342074lifeskim:mentionsumls-concept:C1611588lld:lifeskim
pubmed-article:2342074lifeskim:mentionsumls-concept:C0220821lld:lifeskim
pubmed-article:2342074pubmed:issue6lld:pubmed
pubmed-article:2342074pubmed:dateCreated1990-6-28lld:pubmed
pubmed-article:2342074pubmed:abstractTextThe synthesis of a series of 1,4-dihydropyridines which have N-linked heterocycles at the terminus of an ethoxymethyl chain at the 2-position is described. The calcium antagonist activity on rat aorta of this class of DHPs is compared with their negative inotropic activity as determined by using a Langendorff-perfused guinea pig heart model. The compounds examined show a wide range of selectivity for vascular over cardiac tissue, with those analogues which possess an amide group at the terminus of the 2-substituent proving the most selective. From the in vitro data obtained for a series of 1,2,3-triazoles, it is possible to conclude that the SARs for binding to the calcium channels in vascular and cardiac tissue are different. One of the compounds, 2-amino-1-[2-[[4-(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-5- (methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl]methoxy]ethyl]-4( 3H)- imidazolone (20b, UK-55,444), was identified as a potent (IC50 = 8 x 10(-9) M) calcium antagonist which is 40-fold selective for vascular over cardiac tissue and which has a significantly longer duration of action (greater than 3 h) than nifedipine in the anesthetized dog on intravenous administration.lld:pubmed
pubmed-article:2342074pubmed:languageenglld:pubmed
pubmed-article:2342074pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2342074pubmed:citationSubsetIMlld:pubmed
pubmed-article:2342074pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2342074pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2342074pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2342074pubmed:statusMEDLINElld:pubmed
pubmed-article:2342074pubmed:monthJunlld:pubmed
pubmed-article:2342074pubmed:issn0022-2623lld:pubmed
pubmed-article:2342074pubmed:authorpubmed-author:CarterA JAJlld:pubmed
pubmed-article:2342074pubmed:authorpubmed-author:GardinerD GDGlld:pubmed
pubmed-article:2342074pubmed:authorpubmed-author:BurgesR ARAlld:pubmed
pubmed-article:2342074pubmed:authorpubmed-author:CrossP EPElld:pubmed
pubmed-article:2342074pubmed:authorpubmed-author:CampbellS FSFlld:pubmed
pubmed-article:2342074pubmed:authorpubmed-author:AlkerDDlld:pubmed
pubmed-article:2342074pubmed:issnTypePrintlld:pubmed
pubmed-article:2342074pubmed:volume33lld:pubmed
pubmed-article:2342074pubmed:ownerNLMlld:pubmed
pubmed-article:2342074pubmed:authorsCompleteYlld:pubmed
pubmed-article:2342074pubmed:pagination1805-11lld:pubmed
pubmed-article:2342074pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2342074pubmed:meshHeadingpubmed-meshheading:2342074-...lld:pubmed
pubmed-article:2342074pubmed:meshHeadingpubmed-meshheading:2342074-...lld:pubmed
pubmed-article:2342074pubmed:meshHeadingpubmed-meshheading:2342074-...lld:pubmed
pubmed-article:2342074pubmed:meshHeadingpubmed-meshheading:2342074-...lld:pubmed
pubmed-article:2342074pubmed:meshHeadingpubmed-meshheading:2342074-...lld:pubmed
pubmed-article:2342074pubmed:meshHeadingpubmed-meshheading:2342074-...lld:pubmed
pubmed-article:2342074pubmed:meshHeadingpubmed-meshheading:2342074-...lld:pubmed
pubmed-article:2342074pubmed:meshHeadingpubmed-meshheading:2342074-...lld:pubmed
pubmed-article:2342074pubmed:meshHeadingpubmed-meshheading:2342074-...lld:pubmed
pubmed-article:2342074pubmed:meshHeadingpubmed-meshheading:2342074-...lld:pubmed
pubmed-article:2342074pubmed:meshHeadingpubmed-meshheading:2342074-...lld:pubmed
pubmed-article:2342074pubmed:meshHeadingpubmed-meshheading:2342074-...lld:pubmed
pubmed-article:2342074pubmed:year1990lld:pubmed
pubmed-article:2342074pubmed:articleTitleLong-acting dihydropyridine calcium antagonists. 5. Synthesis and structure-activity relationships for a series of 2-[[(N-substituted-heterocyclyl)ethoxy]methyl]-1,4-dihydropyridine calcium antagonists.lld:pubmed
pubmed-article:2342074pubmed:affiliationPfizer Central Research, Sandwich, Kent, United Kingdom.lld:pubmed
pubmed-article:2342074pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2342074pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:2342074lld:chembl